ArticleInterventional cardiology (London, England)2022
Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention.
Morteza Chehrevar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.